Drug Trial Radar · NCT04604184
ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19
Last checked: Nov 20, 2026Latest source record: Apr 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
133
Actual
Start
Nov 3, 2020
Primary completion
Mar 24, 2021
Study completion May 31, 2021
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Oct 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with COVID-19 infection who are in hospital and receive oxygen. Participants need to be 50 years of age or older and need to be at risk of further worsening of their condition. The purpose of the study is to find out whether a medicine called BI 764198 helps people with COVID-19 infection and breathing problems. BI 764198 may prevent cell death and swelling of the lung tissue and therefore help patients with COVID-19 infection. Participants are put into 2 groups by chance. One group of participants gets BI 764198 capsules and the other group gets placebo capsules. The placebo capsules look exactly like the BI 764198 capsules but do not contain any medicine. Participants take 1 capsule per day. Participants are in the study for about a month. At study end, doctors compare the 2 groups for the number of patients that are alive and do not need mechanical breathing support. During the study, the doctors collect information on any health problems of the participants.
Conditions
- COVID-19
Interventions
BI 764198Drug
BI 764198
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Alive and Free of Mechanical VentilationTime frame: At Day 29
Locations
25 sites in 6 countries. Site status is shown where the registry gives one.
University of California Irvine
Orange, California
Rapides Regional Medical Center
Alexandria, Louisiana
St. Elizabeth's Medical Center
Boston, Massachusetts
Newton-Wellesley Hospital
Newton, Massachusetts
Mercy Health St. Vincent Medical Center
Toledo, Ohio
Providence Regional Medical Center
Everett, Washington
MultiCare Tacoma General Hospital
Tacoma, Washington
Hospital Luxemburgo
Belo Horizonte, Brazil
IPECC - Instituto de Pesquisa Clínica de Campinas
Campinas, Brazil
Hospital Ernesto Dornelles
Porto Alegre, Brazil
Hospital Regional Hans Dieter Schmidt
Santa Catarina, Brazil
Hospital de Base - Fac Med de Sao Jose do Rio Preto
São José do Rio Preto, Brazil
Hospital Padre Alberto Hurtado
Santiago, Chile
Hospital Carlos Van Buren
Valparaíso, Chile
Hospital Cardiologica Aguascalientes
Aguascalientes, Mexico
Hospital General de Culiacán "Dr. Bernardo J. Gastellum"
Culiacán, Mexico
Hospital Universitario Dr Jose Eleuterio Gonzalez
Monterrey, Mexico
Hospital Auxilio Mutuo
Hato Rey, Puerto Rico
Hospital Municipal de San Juan
Rio Piedras, Puerto Rico
Hospital A Coruña
A Coruña, Spain
Hospital General Universitario de Alicante
Alicante, Spain
Hospital Universitario Infanta Leonor
Madrid, Spain
Hospital Clínico San Carlos
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Son Espases
Palma de Mallorca, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.